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Intuitively if one were to consider therapeutics targeted towards microbes, antibiotics may be the first class to come 
to mind. Indeed, microbial medicine in the 20
th
 century exclusively focused on antibiotic-based therapies as an 
essential tool in the arsenal used in the fight against pathogenic bacteria and in the management of infectious disease. 
However, in the 21
st
 century the importance of maintaining an appropriate and diverse microbiome to support 
optimum health across the lifespan has emerged (Dinan & Cryan, 2017). Indeed, the microbiome is one of the most 
exiting areas in modern biomedicine with no discipline untouched by its influence including Pharmacology. Thus, 
this Themed Issue is focused on the relationship between the microbiome and therapeutics opportunities beyond 
antibiotics. 
 
The collateral damage exerted on commensal organisms by antibiotics may have far reaching consequences for the 
host as we gain better insights into the metabolic capacity of the gut microbiome. This is not least, in part, because of 
the microbial transformations which are a key function of the gut microbiota, many of which are established in 
infanthood and later provide a source of essential nutrients, amino acids and minerals (Bik, Ugalde, Cousins, 
Goddard, Richman & Apte, 2018). Therefore, disruption of this dynamic microbial ecosystem may have wide-
ranging consequences on the host. As part of this issue Bik et al., (2018) elegantly summarizes how dietary and host-
derived molecules are utilized by the gut microbiota to yield physiologically significant pre cursors and products 
which may enter the circulation where they can subsequently influence the function of organs and systems distant 
from the gastrointestinal tract.  
 
Such microbial biotransformations are also critical in xenobiotic metabolism, and in the context of therapeutics, for 
example, in the activation and inactivation of drugs (Bik, Ugalde, Cousins, Goddard, Richman & Apte, 2018). These 
drug-bacteria interactions are, of course, subject to variations in the genetic makeup of the microbiome and this in 
combination with the metabolic potential of the gut microbiome is now encompassed by the term, 
Pharmacomicrobiomics (Rizkallah, Saad & Aziz, 2010).   In contrast to the oxidation and conjugation reactions 
which are characteristic of hepatic drug metabolism, reduction and hydrolysis reactions dominate gut microbiota-
mediated metabolic reactions (Haiser & Turnbaugh, 2013; Walsh, Griffin, Clarke & Hyland, 2018). The complexity 
and bi-directional nature of drug-microbe interactions is elaborated upon by Walsh et al., (2018) who review not only 
the direct effects microbes can have on drugs, but who also detail the effects microbiota-derived metabolites can 
have on host drug metabolism.  Therefore, natural variations in the microbiome may underlie variability in drug 
response or toxicity.  
 
Whilst microbes may have traditionally been viewed as the exclusive target of antibiotics, it is now becoming 
increasingly clear that the microbiota is impacted by non-antibiotic drugs (Cussotto et al., 2018; Maier et al., 2018). 
Indeed in a recent  in vitro study where in excess of 1,000 non-antibiotic drugs representative of all main therapeutic 
classes, the majority of which were human-targeted, were screened against a panel of ubiquitous gut bacterial 
species, 24% displayed anti-commensal activity  (Maier et al., 2018). The clinical significance of such findings is 
exemplified by the similarity between antimicrobial-associated side effects and those associated with these human-
targeted drugs. These effects on gut microbial populations are intriguing in that they may provide insight into 
heretofore unexplored mechanisms of action beyond what has been accepted to date. Of note in this regard, is the 
similarity in anti-commensal activity between classes of chemically diverse drugs, such as antipsychotics which have 
molecular targets not normally associated with gut microbes. Whether these microbial effects underpin drug-
associated side effects or contribute to their mechanism of action now warrants further investigation.  For example, 
subjects treated with atypical antipsychotics not only display a characteristic increase in body mass index, but also 
significant changes in their gut microbiome (Flowers, Evans, Ward, McInnis & Ellingrod, 2017). In rodents, at least, 
this clinically significant side-effect could be negated by antibiotic-induced disruption of the gut microbiota (Davey 
et al., 2013). In this Themed Issue the review article by Walsh et al., (2018) concludes by exploring the implications 
of drug-gut interactions for neuropharmacology, whilst Bambury and colleagues propose a pathway for discovery of 
microbial-targeted therapies in psychiatric illness.  
 
The antimicrobial activity of human-targeted drugs also raises further concerns, with the suggestion that human-
targeted drugs may lead to the acquisition of antibiotic resistance (Maier et al., 2018). Though an important and 
underappreciated effect of such drugs, more generally antibiotic resistance has fuelled the drive, or refocused efforts 
in the development of novel antimicrobial strategies. In an associated review aligned to this Themed Issue, ‘Phages 
of life – the path to pharma’, Forde and Hill (2018) examine the therapeutic potential and limitations of developing 
phage in the context of the challenges posed by the World Health Organization’s list of ‘drug-resistant’ priority 
pathogens.  The step-wise progression to ‘pharma’ proposed encompasses an integrated approach between 
physiology, genetics, and pharmacology along with commercial and regulatory considerations (Forde & Hill, 2018). 
Although challenges apply to the therapeutic development of phage, such as the development of resistance and 
delivery, with the application of metagenomic approaches their therapeutic potential, beyond the most urgent need, 
can now be realized as we better understand the role of the microbiome in health and disease.  
 
The concept that manipulation of the gut microbiota, by drugs or otherwise, unlocks new avenues for the 
management of clinically significant disorders. For instance the concept that psychobiotics, defined as live organisms 
that, when ingested in adequate amounts, produces a health benefit in patients suffering from psychiatric illness, as a 
novel class of psychotropic is gaining traction  (Dinan, Stanton & Cryan, 2013). Any such microbial intervention is 
likely, however, to need to exert pleotropic effects on the host across inflammatory and endocrine pathways (Dinan, 
Stanton & Cryan, 2013). Bambury and colleagues (2018) discuss the application of inter-omic methods, integrating 
metagenomic, proteomic and metabolomic approaches, in hastening the discovery of novel microbial therapeutics 
and present a rational and systematic approach to be adopted in order to realize the identification of novel 
psychobiotics (Bambury, Sandhu, Cryan & Dinan, 2017).  
 
However, such approaches are not limited to psychiatric illness given that the microbiome, the metabolites it can 
produce and its effects on host homeostasis are of equal relevance to other body systems. For example, bacterial 
derived trimethylamine is a substrate for host flavin monooxygenases which gives rise to trimethylamine N-oxide 
which has been implicated in cardiovascular disease (Kiouptsi & Reinhardt, 2018). As in psychiatric illness, the 
underlying pathophysiology of cardiovascular disease is unlikely to involve a single microbial-associated mechanism 
and in this regard microbial associated molecular patterns and their recognition systems have also been implicated in 
the development of atherosclerosis (Kiouptsi & Reinhardt, 2018). Kiouptsi & Reinhardt (2018) therefore propose 
that pattern recognition receptors, such as toll-like receptors, may not be the only prospective microbial-associated 
therapeutic targets, but also suggest that targeting bacterial enzymatic pathways implicated in the pathophysiology of 
cardiovascular disease and atherosclerosis may be equally valid with proof-of-concept studies demonstrating that 
non-lethal inhibition of trimethylamine may be therapeutically relevant (Wang et al., 2015).  
 
We are only beginning to fully appreciate the relationship between the microbiome, pharmacology and therapeutics. 
It is clear that the gut microbiota is a rich reservoir for metabolites that act on pharmacological targets (Cohen et al., 
2017; Cryan, Clarke, Dinan & Schellekens, 2018; Stilling, van de Wouw, Clarke, Stanton, Dinan & Cryan, 2016). 
The editors hope that the articles contained in this themed section will prove useful in providing an introduction to 
the biologically significant biotransformations carried out by the gut microbiota, and, how, as we better understand 
these processes through the application of new technologies, may yield novel drug targets. This is exemplified in the 
context of cardiovascular disease and atherosclerosis.   The significance of drug-gut microbiota interactions are 
highlighted, which may skew our traditional understanding of pharmacokinetics and pharmacodynamics, and will 
undoubtedly have to be considered as a significant factor in the development of new drugs, either microbial- or host-
targeted. And finally, we introduce rational approaches which can be applied to the discovery, and application of, 
therapeutic phage and novel psychotropics.  
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